IL254907B - De novo binding domain containing polypeptides and uses thereof - Google Patents

De novo binding domain containing polypeptides and uses thereof

Info

Publication number
IL254907B
IL254907B IL254907A IL25490717A IL254907B IL 254907 B IL254907 B IL 254907B IL 254907 A IL254907 A IL 254907A IL 25490717 A IL25490717 A IL 25490717A IL 254907 B IL254907 B IL 254907B
Authority
IL
Israel
Prior art keywords
binding region
region containing
containing polypeptides
novel binding
novel
Prior art date
Application number
IL254907A
Other languages
English (en)
Hebrew (he)
Other versions
IL254907A0 (en
Inventor
David William Lafleur
David M Hilbert
Original Assignee
Subdomain Llc
Arcellx Inc
David William Lafleur
David M Hilbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Subdomain Llc, Arcellx Inc, David William Lafleur, David M Hilbert filed Critical Subdomain Llc
Publication of IL254907A0 publication Critical patent/IL254907A0/en
Publication of IL254907B publication Critical patent/IL254907B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C07K16/11—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
IL254907A 2015-04-06 2017-10-06 De novo binding domain containing polypeptides and uses thereof IL254907B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143772P 2015-04-06 2015-04-06
PCT/US2016/025868 WO2016164305A1 (en) 2015-04-06 2016-04-04 De novo binding domain containing polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
IL254907A0 IL254907A0 (en) 2017-12-31
IL254907B true IL254907B (en) 2021-05-31

Family

ID=57072017

Family Applications (2)

Application Number Title Priority Date Filing Date
IL254907A IL254907B (en) 2015-04-06 2017-10-06 De novo binding domain containing polypeptides and uses thereof
IL282704A IL282704A (en) 2015-04-06 2021-04-27 De novo binding domain containing polypeptides and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL282704A IL282704A (en) 2015-04-06 2021-04-27 De novo binding domain containing polypeptides and uses thereof

Country Status (26)

Country Link
US (8) US10647775B2 (enExample)
EP (3) EP3280432B8 (enExample)
JP (5) JP6873101B2 (enExample)
KR (2) KR20250048140A (enExample)
CN (4) CN115160438A (enExample)
AU (4) AU2016246426B2 (enExample)
BR (1) BR112017021308A2 (enExample)
CA (2) CA2981616C (enExample)
CY (1) CY1124453T1 (enExample)
DK (2) DK3280432T3 (enExample)
EA (1) EA201792226A1 (enExample)
ES (2) ES2901273T3 (enExample)
HR (1) HRP20210498T1 (enExample)
HU (1) HUE054435T2 (enExample)
IL (2) IL254907B (enExample)
LT (1) LT3280432T (enExample)
MX (2) MX387517B (enExample)
PH (1) PH12017501834B1 (enExample)
PL (1) PL3280432T3 (enExample)
PT (1) PT3280432T (enExample)
RS (1) RS61907B1 (enExample)
SG (2) SG10202007987QA (enExample)
SI (1) SI3280432T1 (enExample)
SM (1) SMT202100285T1 (enExample)
WO (3) WO2016164305A1 (enExample)
ZA (1) ZA201706875B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
CA2981616C (en) * 2015-04-06 2025-06-17 Arcellx, Inc. De novo binding domain polypeptides and their uses
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP2020507577A (ja) * 2017-02-10 2020-03-12 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
CA3054642A1 (en) * 2017-02-10 2018-08-16 Dragonfly Therapeutics, Inc. Proteins binding bcma, nkg2d and cd16
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018209052A1 (en) 2017-05-10 2018-11-15 Wellstat Immuno Therapeutics, Llc Enveloped virus resistant to complement inactivation for the treatment of cancer
CN107216395B (zh) * 2017-07-03 2018-07-20 上海科医联创生物科技有限公司 一种tm4sf1特异性嵌合抗原受体及其应用
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
JP7303802B2 (ja) * 2017-09-23 2023-07-05 メモリアル スローン ケタリング キャンサー センター Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
EP3706801B1 (en) 2017-11-08 2026-01-14 L.E.A.F Holdings Group LLC Platinum complexes and uses thereof
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
BR112020009136A2 (pt) * 2017-11-14 2020-10-13 Arcellx, Inc. polipeptídeos que contêm domínio d e usos dos mesmos
IL274677B2 (en) * 2017-11-14 2025-01-01 Arcellx Inc Therapies with multifunctional immune system cells
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
JP2021512914A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
SG11202007945UA (en) 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019178518A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
MA52571A (fr) 2018-05-08 2021-03-17 Amgen Inc Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables
WO2020014261A1 (en) 2018-07-09 2020-01-16 The Broad Institute, Inc. Rna programmable epigenetic rna modifiers and uses thereof
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20250112921A (ko) * 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB201903479D0 (en) * 2019-03-14 2019-05-01 Univ Oxford Innovation Ltd Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof
BR112021018607A2 (pt) 2019-03-19 2021-11-23 Massachusetts Inst Technology Métodos e composições para editar sequências de nucleotídeos
JP2022527351A (ja) * 2019-04-02 2022-06-01 イーライ リリー アンド カンパニー 結合ペプチドを選択し検出するための方法
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN111848733B (zh) * 2019-04-30 2024-03-12 上海细胞治疗集团有限公司 一种多肽组合物及疫苗
MX2021014334A (es) * 2019-05-24 2022-02-21 Avitide LLC Agentes afines a aav9.
JP2022535511A (ja) * 2019-05-31 2022-08-09 ルーブリック・セラピューティクス・インコーポレイテッド メソスケール操作されたペプチドおよび選択方法
EP4010031A1 (en) 2019-08-06 2022-06-15 L.E.A.F Holdings Group LLC Processes of preparing polyglutamated antifolates and uses of their compositions
JPWO2021100585A1 (enExample) * 2019-11-20 2021-05-27
WO2021115333A1 (zh) * 2019-12-10 2021-06-17 苏州克睿基因生物科技有限公司 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用
BR112022021884A2 (pt) 2020-05-06 2022-12-20 Dragonfly Therapeutics Inc Proteínas que se ligam a nkg2d, cd16 e clec12a
CN111560391B (zh) * 2020-05-21 2022-02-11 北京大学 一种蛋白质异质索烃的生物合成方法
CN111732635B (zh) * 2020-06-22 2022-03-22 中国医学科学院基础医学研究所 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用
WO2022006564A1 (en) * 2020-07-03 2022-01-06 The Trustees Of Columbia University In The City Of New York Polyfunctional orthogonal protein chimeras
CN114380907B (zh) * 2020-10-16 2024-06-18 中国科学院上海药物研究所 靶向cmtm6的纳米抗体及其制备方法和应用
CA3208273A1 (en) * 2021-01-20 2022-07-28 Coding Bio Limited Methods for high throughput screening of chimeric antigen receptors
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
EP4313083A4 (en) 2021-03-26 2025-06-18 Arcellx, Inc. MULTIFUNCTIONAL IMMUNE CELL THERAPIES
CN118679180A (zh) 2021-11-15 2024-09-20 阿奇利克斯股份有限公司 包含d结构域的多肽及其用途
US20250170182A1 (en) * 2022-02-18 2025-05-29 Dana-Farber Cancer Institute, Inc. Epitope engineering of cell-surface receptors
AU2023233593A1 (en) * 2022-03-17 2024-09-05 Singular Immune, Inc Composition and method of use recombinant fusion protein to generate car-immune cells
CN119365491A (zh) * 2022-04-27 2025-01-24 得克萨斯大学体系董事会 基于cd30铰链和/或跨膜结构域的嵌合抗原受体
CN115028689B (zh) * 2022-06-15 2023-05-30 浙江东方基因生物制品股份有限公司 特异性检测hpv6和hpv11的双特异性检测试剂盒
CN116380854B (zh) * 2023-03-06 2025-05-30 上海电力大学 一种基于荧光光谱快速检测水中微塑料污染的方法
WO2024254346A1 (en) * 2023-06-07 2024-12-12 The Broad Institute, Inc. Engineered viral like particles (evlps) for the selective transduction of target cells
WO2025122460A1 (en) * 2023-12-04 2025-06-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
CA2267139A1 (en) 1996-10-08 1998-04-16 Ton Logtenberg Methods and means for selecting peptides and proteins having specific affinity for a target
US7763258B2 (en) 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
DE19802708A1 (de) 1998-01-24 1999-07-29 Hoechst Marion Roussel De Gmbh Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren
EP1469883A2 (en) 1998-02-19 2004-10-27 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP2067788B1 (en) 1999-05-18 2015-07-22 Dyax Corp. Fab fragment libraries and methods for their use
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US6815184B2 (en) 2000-07-31 2004-11-09 Biolex, Inc. Expression of biologically active polypeptide in duckweed
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US8932825B2 (en) 2001-12-27 2015-01-13 Glycofi Inc. Method to engineer mammalian-type carbohydrate structures
WO2003061570A2 (en) 2002-01-16 2003-07-31 Zyomyx, Inc. Engineered binding proteins
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
KR101070518B1 (ko) 2002-03-19 2011-10-05 스티칭 디엔스트 랜드보위쿤디그 온데조에크 식물에서의 ｇｎｔⅲ 발현
EP2385118A1 (en) 2002-09-06 2011-11-09 Isogenica Limited In vitro peptide expression library
ES2347325T3 (es) 2002-09-12 2010-10-28 Greenovation Biotech Gmbh Metodo de produccion de proteinas.
JP4559358B2 (ja) 2002-12-20 2010-10-06 グリーンオベーション バイオテク ゲーエムベーハー コケ細胞における異種グリコシル化タンパク質の産生
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2005024044A2 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
EP1675607B1 (en) 2003-09-05 2015-10-21 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
WO2007019376A2 (en) * 2005-08-03 2007-02-15 Rq Bioscience, Inc. Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
GB0907251D0 (en) 2009-04-28 2009-06-10 Univ Leiden Coplymers
US20120172419A1 (en) 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012167109A2 (en) 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Rpgrip1 gene therapy for leber congenital amaurosis
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
AU2013318928A1 (en) 2012-09-21 2015-04-09 Kaneka Corporation Protein ligand for affinity isolation matrix
US9840539B2 (en) * 2013-03-14 2017-12-12 University Of Washington Through Its Center For Commercialization High affinity digoxigenin binding proteins
US20160031996A1 (en) 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
GB201306634D0 (en) 2013-04-11 2013-05-29 Univ Bristol Cage-like particles
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
JP6741591B2 (ja) 2014-05-02 2020-08-19 ジェンザイム・コーポレーション 網膜およびｃｎｓ遺伝子治療用ａａｖベクター
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
CA2981616C (en) 2015-04-06 2025-06-17 Arcellx, Inc. De novo binding domain polypeptides and their uses
KR20160126340A (ko) 2015-04-23 2016-11-02 삼성전자주식회사 3중-나선 다발 단백질 및 이의 용도
AU2016353067B2 (en) 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
CA3041582A1 (en) 2016-11-02 2018-05-11 Universitat Basel Immunologically discernible cell surface variants for use in cell therapy
CN107254447B (zh) 2017-06-01 2020-10-16 刘未斌 Anti AFP CAR-T细胞及其制备方法和应用
BR112020009136A2 (pt) 2017-11-14 2020-10-13 Arcellx, Inc. polipeptídeos que contêm domínio d e usos dos mesmos
IL274677B2 (en) 2017-11-14 2025-01-01 Arcellx Inc Therapies with multifunctional immune system cells
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
EP4313083A4 (en) 2021-03-26 2025-06-18 Arcellx, Inc. MULTIFUNCTIONAL IMMUNE CELL THERAPIES
CN118679180A (zh) 2021-11-15 2024-09-20 阿奇利克斯股份有限公司 包含d结构域的多肽及其用途
CA3275338A1 (en) 2022-11-29 2024-06-06 Arcellx, Inc. D-DOMAIN POLYPEPTIDES AND ASSOCIATED USES

Also Published As

Publication number Publication date
US20200223934A1 (en) 2020-07-16
PT3280432T (pt) 2021-04-22
EP3280433B1 (en) 2021-09-15
MX2021013161A (es) 2021-12-10
LT3280432T (lt) 2021-06-25
DK3280433T3 (da) 2021-11-15
MX2017012679A (es) 2018-02-09
DK3280432T3 (da) 2021-04-26
JP6871232B2 (ja) 2021-05-12
JP2018516092A (ja) 2018-06-21
HRP20210498T1 (hr) 2021-06-25
US20250353920A1 (en) 2025-11-20
EP3280432A4 (en) 2018-11-07
RS61907B1 (sr) 2021-06-30
SG10202007987QA (en) 2020-09-29
HUE054435T2 (hu) 2021-09-28
MX387517B (es) 2025-03-18
US12358995B2 (en) 2025-07-15
AU2021200810A1 (en) 2021-03-04
AU2023219820B2 (en) 2025-01-30
BR112017021308A2 (pt) 2018-09-25
ES2866202T3 (es) 2021-10-19
NZ774195A (en) 2024-09-27
HK1249422A1 (en) 2018-11-02
CN107708720A (zh) 2018-02-16
JP2018513212A (ja) 2018-05-24
WO2016164369A3 (en) 2016-11-17
AU2023219820A1 (en) 2023-09-07
EP3280433A1 (en) 2018-02-14
CN107921090A (zh) 2018-04-17
CA2981711A1 (en) 2016-10-13
KR20180012747A (ko) 2018-02-06
US20180251521A1 (en) 2018-09-06
KR102788389B1 (ko) 2025-03-31
ZA201706875B (en) 2021-10-27
WO2016164308A1 (en) 2016-10-13
US20200362046A1 (en) 2020-11-19
JP7244567B2 (ja) 2023-03-22
JP2024075751A (ja) 2024-06-04
IL254907A0 (en) 2017-12-31
AU2025202871A1 (en) 2025-05-15
JP2023052563A (ja) 2023-04-11
US10662248B2 (en) 2020-05-26
PH12017501834B1 (en) 2024-01-17
US20210230288A1 (en) 2021-07-29
HK1249421A1 (en) 2018-11-02
EP3280432B1 (en) 2021-03-10
KR20250048140A (ko) 2025-04-07
ES2901273T3 (es) 2022-03-21
JP2021106605A (ja) 2021-07-29
PL3280432T3 (pl) 2021-09-27
AU2016246426A1 (en) 2017-10-26
CY1124453T1 (el) 2022-07-22
JP6873101B2 (ja) 2021-05-19
CN115160438A (zh) 2022-10-11
US20180209983A1 (en) 2018-07-26
EP3280433A4 (en) 2018-10-31
SI3280432T1 (sl) 2021-09-30
AU2021200810B2 (en) 2023-05-25
EA201792226A1 (ru) 2018-08-31
WO2016164369A2 (en) 2016-10-13
US11008397B2 (en) 2021-05-18
EP3280432A1 (en) 2018-02-14
US20210002381A1 (en) 2021-01-07
EP3280432B8 (en) 2021-04-14
US10647775B2 (en) 2020-05-12
IL282704A (en) 2021-06-30
US20240043550A1 (en) 2024-02-08
EP3903804A1 (en) 2021-11-03
WO2016164305A1 (en) 2016-10-13
PH12017501834A1 (en) 2018-04-23
AU2016246426B2 (en) 2020-11-12
CA2981616C (en) 2025-06-17
US20180251563A1 (en) 2018-09-06
CA2981616A1 (en) 2016-10-13
NZ736022A (en) 2024-02-23
CN120424177A (zh) 2025-08-05
SMT202100285T1 (it) 2021-07-12
SG11201708257UA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
IL282704A (en) De novo binding domain containing polypeptides and uses thereof
IL272524A (en) Clec9a binding agents and use thereof
IL262437A (en) Bispecific binding proteins and uses thereof
IL246921B (en) Binding proteins and methods of use thereof
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
IL254516A0 (en) Proteins specific for cd137
DK3157552T3 (da) Syntac-polypeptider og anvendelser deraf
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
PL3496173T3 (pl) Materiał perowskitowy
DK4089113T3 (da) Polypeptider
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3169741T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK3169733T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
EP3362556C0 (en) POLYPEPTIDE VARIANTS
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3242892T3 (da) Modificerede april-bindende antistoffer
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3145945T3 (da) Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
EP3506964C0 (en) BINDING SYRINGE
DK3319641T3 (da) Nye PSMA-specifikke bindingsproteiner
IL254591A0 (en) Polypeptides
DK3245224T3 (da) Il-17a-bindende polypeptider
GB201608197D0 (en) Novel proteins
EP3532537A4 (en) Material sets

Legal Events

Date Code Title Description
FF Patent granted